Rehovot

VBI Vaccines Reports First Quarter 2024 Financial Results

Retrieved on: 
수요일, 5월 15, 2024
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, Shekel, GBM, Partnership, Patient, Hepatitis B vaccine, CAD, VBI, Research and development, Vaccine, Control arm, Survival, Government, Israeli new shekel, Disease, Net, Bank statement, Sale, Public, Jefferies Group, IDN, GAAP, Carmustine, MLE, Intellectual property, Administration, Rehovot, Postal Index Number, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2024.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2024.
  • Revenues, net: Revenues, net for the first quarter 2024 were $1.2 million as compared to $0.5 million for the same period in 2023.
  • Cost of Revenues: Cost of revenues was $2.7 million in the first quarter of 2024 as compared to $3.6 million in the first quarter of 2023.
  • Foreign exchange loss for the first quarter of 2024 was $4.3 million as compared to $6.8 million for the first quarter of 2023.

Maris-Tech to Showcase Its Innovative Solutions at the Special Operations Forces Week

Retrieved on: 
목요일, 4월 11, 2024
Acceleration, AI, Rehovot, Booth, Ministry, Nightclub

Rehovot, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of AI accelerated video solutions for edge platforms, today announced its participation in the upcoming Special Operations Forces (SOF) Week, which will take place from May 6 to May 9, 2024,in Tampa, Florida.

Key Points: 
  • The annual conference for U.S. and international special operations forces is expected to host more than 15,000 attendees
    Rehovot, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of AI accelerated video solutions for edge platforms, today announced its participation in the upcoming Special Operations Forces (SOF) Week, which will take place from May 6 to May 9, 2024,in Tampa, Florida.
  • The Company will demonstrate the capabilities of its innovative solutions with AI acceleration capabilities suitable for professional and tactical operations.
  • “Maris-Tech’s participation at SOF Week, a highly regarded conference, is part of our efforts to penetrate the U.S. defense industry while focusing on special operations forces and diverse defense platforms, such as unmanned vehicles and other autonomous remote platforms,” said Israel Bar, Chief Executive Officer of Maris-Tech.
  • Maris-Tech will exhibit at Booth #1933 on the Israeli Ministry of Defense Pavilion.

Maris-Tech Announces Collaboration with Global Semiconductor Powerhouse Renesas Electronics Corporation to Advance Edge Computing Solutions and Acceptance into its Preferred Partner Program

Retrieved on: 
월요일, 3월 25, 2024
Internet of things, Artificial intelligence, Renesas Electronics, AI, Edge, Rehovot

Rehovot, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a leading B2B provider of artificial intelligence (AI) accelerated video solutions for edge platforms, today announced a collaboration with Renesas Electronics Corporation (“Renesas”), one of the world’s largest semiconductor manufacturers, a global innovator in the field of microcontrollers, analog, and power devices, and acceptance into Renesas’ Preferred Partner Program.  In fiscal year 2023, Renesas had annual revenues in excess of US $9 billion and a market cap in excess of US $30 billion as of March 23, 2024.* This relationship has the potential to revolutionize commercial, security, and space markets through innovative edge-computing developments.

Key Points: 
  • * This relationship has the potential to revolutionize commercial, security, and space markets through innovative edge-computing developments.
  • Renesas combines its expertise in embedded processing, analog, power and connectivity to deliver complete semiconductor solutions.
  • Through this collaboration, Maris-Tech's AI and video analytics expertise will leverage Renesas's robust portfolio of microcontrollers to pioneer groundbreaking edge computing solutions.
  • "We are privileged to be selected as a Renesas Preferred Partner and a testament to Maris-Tech's ambition to redefine the Edge Computing landscape," said Israel Bar, Chief Executive Officer of Maris-Tech.

BioHarvest Sciences Signs First Contracts with Two Industrial Customers to Develop Complex Molecules via Its Newly Launched Botanical Synthesis CDMO Business Unit

Retrieved on: 
월요일, 2월 26, 2024
Steps, Biotechnology, Food, Confidentiality, Plant, Biomass, NRE, Entrepreneurship, CDMO, Step, Safety, BHSC, Rehovot, Fine chemical

The new business unit allows pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders the opportunity to partner with BioHarvest to utilize its Botanical Synthesis Process technology through a typical CDMO contracting model.

Key Points: 
  • The new business unit allows pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders the opportunity to partner with BioHarvest to utilize its Botanical Synthesis Process technology through a typical CDMO contracting model.
  • This proprietary process technology enables the development and manufacturing of patentable plant based small molecules, complex molecules, and unique compositions which include both small and complex molecules.
  • As a result of these advantages, the Company has decided to call these unique plant-derived complex molecules BIOLOGICS+.
  • The CDMO business offers the Botanical Synthesis process technology in 3 major steps to its customers.

Maris-Tech Receives Repeat Order for Approximately $600,000 with an Option to Increase to Approximately $730,000 from a Company in the Defense Industry for its Unique Situational Awareness Solution

Retrieved on: 
수요일, 2월 21, 2024
Artificial intelligence, Rehovot

Rehovot, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of artificial intelligence (“AI”) accelerated video solutions for edge platforms, today announced that it has received a repeat order for approximately $600,000 from a leading company in the defense industry for a customized solution, that provides armored and autonomous vehicles with enhanced situational awareness. The customer also has an option to increase the order by $130,000 to approximately $730,000.

Key Points: 
  • The customer also has an option to increase the order by $130,000 to approximately $730,000.
  • The situational awareness system is based on Maris-Tech’s powerful Jupiter AI platform, incorporating advanced video streaming, recording, and AI-based capabilities that provide real-time intelligence to armored and autonomous vehicles.
  • The repeat order was received after the systems were installed and field-proven to the end customer’s complete satisfaction and approval.
  • The first order, as the Company announced on November 22, 2023, was for approximately $687,000, including exercising the customer’s option, reaching a total amount for the two orders of approximately $1,287,000 (or approximately $1,417,000 if the customer exercises the option in the current order).

BioHarvest Sciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

Retrieved on: 
목요일, 2월 15, 2024
Social media, Biotechnology, Innovation system, Health, Plant, City, BHSC, Synthesis, Alternative medicine, Rehovot, Wellness, Science, Fine chemical

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 15, 2024) - BioHarvest Sciences Inc. , (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company"), a biotechnology company pioneering botanical synthesis, has engaged investor relations specialists MZ Group (MZ) to lead a strategic investor relations and financial communications program across all key markets.

Key Points: 
  • Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 15, 2024) - BioHarvest Sciences Inc. , (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company"), a biotechnology company pioneering botanical synthesis, has engaged investor relations specialists MZ Group (MZ) to lead a strategic investor relations and financial communications program across all key markets.
  • MZ will work closely with BioHarvest management to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community.
  • The company's first commercialized grape-derived product, VINIA®, is driving strong revenue growth as BioHarvest continues the launch of incremental product lines.
  • Individuals performing the services at MZ will be entitled to receive consultant options when granted by the board of BioHarvest.

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

Retrieved on: 
수요일, 2월 14, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Burn, GBM, Vaccine, Patient, Rehovot, Disease, VBI, Public

Additionally, subject to certain approvals, VBI and Brii Bio will work together to transfer the manufacturing technologies of VBI-2601 to a site designated by Brii Bio.

Key Points: 
  • Additionally, subject to certain approvals, VBI and Brii Bio will work together to transfer the manufacturing technologies of VBI-2601 to a site designated by Brii Bio.
  • VBI received $2.5 million of consideration upon signing of definitive documents and is expected to receive up to an additional $30.5 million of consideration, subject to achievement of certain activities, with a target completion date of June 30, 2024.
  • Jeff Baxter, President and CEO of VBI, stated: “We believe that this transaction improves the financial stability of VBI and balances the potential value creation within our development and commercial portfolio with a streamlined and focused resource deployment.
  • Upon successful completion of all transactions, we anticipate that we will have reduced the long-term burn of the company, and reduced our debt overhang by about 70%.

BIRD - Israel-U.S. Binational Industrial R&D Foundation to invest $9.6 million in 10 new projects: The approved projects, with an overall budget of $24.5 million, involve innovations in the areas of Agrotech, Biotechnology, Electronics, Energy, Foodtech,

Retrieved on: 
수요일, 1월 31, 2024
Misgav, MD, BIRD Foundation, Commerce, BIRD, Planner, Associate, Partnership, Yokneam Illit, Mayo Clinic, History, TEL, Carbon, Splenic infarction, Lod, Intelligence, Sheba Medical Center, Patient, Ministry, Mondelez International, NIST, Approval, Virtual reality, Anopheles, Agriculture, Anopheles stephensi, Parity, Rehovot, ATCC, Hope, Malaria, Pharmaceutical industry

In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.

Key Points: 
  • In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.
  • The BIRD Foundation promotes collaborations between U.S. and Israeli companies in various technological sectors for joint product development.
  • In addition to providing conditional grants of up to $1.5 million, the Foundation assists by working with companies to identify potential strategic partners and facilitate introductions.
  • The ten projects approved by the Board of Governors are in addition to the over 1000 projects that the BIRD Foundation has approved for funding during its 46-year history.

A Record Revenue Year for Maris-Tech.

Retrieved on: 
목요일, 1월 11, 2024
Artificial intelligence, Bank statement, Annual report, Rehovot

Rehovot, Israel, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK) ("Maris-Tech" or the "Company"), a B2B provider of edge computing artificial intelligence (AI) accelerated video solutions for edge platforms, today announced preliminary and partial results for 2023.

Key Points: 
  • Moreover, this financial information has been prepared solely on the basis of currently available information and is the responsibility of management.
  • This preliminary and partial financial information is not a comprehensive statement of our financial results for this period.
  • The Company expects to publish its full financial statements for the year 2023 during March 2024.
  • Our actual results and financial condition may differ materially from those indicated in the forward-looking statements.

Maris-Tech Receives $625,000 Follow-On Order for its Opal Platform from a Leading Defense Company

Retrieved on: 
화요일, 10월 31, 2023
Artificial intelligence, Rehovot, AI, Opal, Acceleration, Israel Beer

Rehovot, Israel, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of artificial intelligence (“AI”) accelerated video solutions for edge platforms, today announced a $625,000 repeat order for units of the Company’s Opal platform from a leading Israeli defense company.

Key Points: 
  • Order underscores the advanced capabilities, high performance and successful application of Maris-Tech’s innovative products in the defense market
    Rehovot, Israel, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of artificial intelligence (“AI”) accelerated video solutions for edge platforms, today announced a $625,000 repeat order for units of the Company’s Opal platform from a leading Israeli defense company.
  • The advanced Opal platform is based on Maris-Tech’s flagship Jupiter AI platform, a high-end multiple stream video platform with AI acceleration that delivers real-time intelligence gathering and analytics.
  • Maris-Tech has already delivered previously placed purchase order in the amount of $500,000 for the Opal platform.
  • Maris-Tech expects to deliver the units pursuant to this purchase order during the years 2023 and 2024.